FDA Orange Book
Generic for Lozol
Lozol contains indapamide. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Lozol is indapamide. 3 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
Run it in Rivvi
Map Lozol and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Lozol products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, oral | 1.25MG | Discontinued | None | 3 | AB |
| tablet, oral | 2.5MG | Discontinued | None | 3 | AB |
NDA 018538, held by SANOFI AVENTIS US LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic indapamide
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| ANI PHARMACEUTICALS INC | 074299 | AB (A-rated, therapeutically equivalent) | April 29, 1996 | 1.25MG, 2.5MG |
| ACTAVIS ELIZABETH LLC | 074722 | AB (A-rated, therapeutically equivalent) | June 17, 1996 | 1.25MG, 2.5MG |
| RISING PHARMA HOLDINGS INC | 074461 | AB (A-rated, therapeutically equivalent) | March 26, 1997 | 1.25MG, 2.5MG |
Questions
Is there a generic for Lozol?
Yes. The generic name for Lozol is indapamide. 3 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
What is the generic name for Lozol?
The active ingredient in Lozol is indapamide, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.